Discovery of a Biased Keap1-p62 PPI Inhibitor for p62 Aberrant HCC

13 is a biased inhibitor of the Keap1–phosphorylated p62 protein-protein interaction with an IC50 of 0.11 μM. The dataset, authored by Ziquan Zhao and shared on figshare in May 2026, likely contains experimental data supporting the discovery of this compound as a targeted Nrf2 inhibition therapy for hepatocellular carcinoma. It includes results from fluorescence polarization assays and in vitro studies showing compound 13 sensitized p62 aberrant HCC to sorafenib-induced ferroptosis with a tumor growth inhibition of 95.3%.

Use Cases

• Training ML models for PPI inhibitor activity prediction based on fluorescence polarization assay data.
• Validating computational docking studies for Keap1-p62 interaction inhibitors.
• Analyzing structure-activity relationships for biased inhibitors targeting specific protein interactions.
• Investigating therapeutic synergy between Nrf2 inhibitors and ferroptosis inducers like sorafenib.

Strengths

• Includes a specific IC50 value (0.11 μM) for the reported inhibitor's activity.
• Reports a concrete therapeutic outcome with a tumor growth inhibition (TGI) value of 95.3%.
• Focuses on a specific, promising oncogenic target (Nrf2) for cancer therapy.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is small (325.7 KB), indicating a limited scope of data.

Provenance

Source

figshare

Collection Method

Likely contains experimental data from fluorescence polarization assays and cell-based studies.

Freshness

Last updated 2026-05-30 13:35:49; freshness should be verified.